HOME >> MEDICINE >> NEWS
Anti-Depressant Drug Shows Promise As Weight-Loss Treatment

g during the first eight weeks appear to be losing additional weight as the treatment is continued past the six-month mark, said Gadde, although researchers have not completed analysis of these data yet. "Here we have a well-tolerated drug that has shown significant clinical benefits in reducing weight," Gadde said. "While we have to approach the results cautiously because the long-term results are not completed, we are very excited about the potential this drug has for treating obesity."

A newer-generation anti-depressant, bupropion SR is in a class by itself and has no appreciable effect on the brain chemical serotonin, as do the majority of newer anti-depressants. Bupropion SR works by increasing available amounts of norepinephrine and dopamine, two other brain chemicals implicated in the reward and pleasure pathways.

Gadde says its unique mechanism of action may account for why patients remark that bupropion does not suppress their appetite, but rather helps them feel satisfied more easily. "A lot of patients have said that, while on the drug, they can eat a small piece of pie and feel satisfied, although not necessarily full. So it appears they feel rewarded much quicker than they normally do without the drug." The only side effect commonly reported in this study was dry mouth. Burpopion SR is not approved by the FDA for weight loss and should not be used by patients with seizure disorders, anorexia or bulimia, Gadde said.

The study will continue for another 18 months. Data also are being collected on bone density and lean muscle mass. Preliminary results should be available later this summer.


'"/>

Contact: Rebecca Levine
Levin005@mc.duke.edu
919-684-4148
Duke University Medical Center
18-May-1999


Page: 1 2

Related medicine news :

1. Study Finds Psychotherapy And Anti-Depressants Equally Effective In Treating Severely Depressed Primary-Care Patients
2. Anti-Depressants: Miracle Drugs Or Placebos With A Buzz?
3. Personality, Thought To Be Stable Over Time, Changes In Healthy People Who Take A Widely Used Anti-Depressant
4. Randomized Contolled Study Shows Neostigmine Is An Effective Treatment For Acute Colonic Pseudo-Obstruction
5. Research Shows That Noncompliance Is Responsible For Half The Cases Of Nonresponse To Antihypertensive Drug Treatment
6. Anal Cancer Screening For HIV-Positive Gay And Bisexual Men Would Save Lives And Be Cost Effective, New Study Shows
7. UCSF Study Shows That An Herbal Therapy Reduces PSA Levels By Half In Men With Advanced Prostate Cancer
8. Evidence Shows Drug-Psychotherapy Combo Effective For Chronic Depression
9. Research Shows Religion Plays A Major Role In Health, Longevity
10. Balloon Procedure In The Brain? Longest Follow-Up To Date Shows Good Results
11. Study Shows Dermatologists Are Best At Removing Skin Cancers

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Anti Depressant Drug Shows Promise Weight Loss Treatment

(Date:4/17/2014)... One of the most popular vaccine brands for children ... may be overlooking some cost factors when choosing vaccines, ... expensive option, according to a new study by University ... administer can be driven by numerous factors," says Sheldon ... professor of computer science and of mathematics at the ...
(Date:4/17/2014)... of California, San Diego School of Medicine report that ... a recent major loss are more likely to be ... study is published in this month,s issue of the ... compassionate behaviors are associated with better health and well-being ... ways to improve the outcomes of individuals whose deficits ...
(Date:4/17/2014)... Jon McCullers, MD, was recently invited to submit ... Nature Reviews Microbiology , one of the world,s ... infectious disease specialist, and chair of the Department ... Science Center, analyzed the epidemiology and microbiology of ... as well as more recent 2009 novel H1N1 ...
(Date:4/17/2014)... MAYWOOD, Il. (April 17, 2014) Doctors who ... disease called lymphangioleiomyomatosis (LAM) can face an agonizing ... progression of the disease and help relieve shortness ... lung transplants, and sirolimus can cause potentially fatal ... said pulmonologist Dr. Daniel Dilling, medical director of ...
(Date:4/17/2014)... 17, 2014-- Colic affects about one in five infants ... pediatric visits during the first several months after birth. ... was showing promise; however, the April 1, 2014 issue ... Valerie) reported on a study, "Probiotics and Infant Colic," ... reuteri for infant colic did not reduce ...
Breaking Medicine News(10 mins):Health News:Study recalculates costs of combination vaccines 2Health News:The ilk of human kindness 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Drug Delivery Systems -- Focus on End ... STUDY OBJECTIVES A drug ...
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical company ... obese patients, today announced initial results from its ... of methionine aminopeptidase 2 (MetAP2), in patients with ... obesity.  These results showed improvements in body weight, ...
(Date:1/14/2014)... HeartWare International, Inc . (NASDAQ: ... circulatory support technologies that are revolutionizing the treatment of ... for the fourth quarter of 2013 will be approximately ... $208 million. "Our full-year revenue growth of ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
Cached News: